A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats

Influenza and other Respiratory Viruses

Volumn 7, Issue 6, 2013, Pages 1227-1236

  Kamphuis, Tobias ^a   Stegmann, Toon ^a,b   Meijerhof, Tjarko ^a   Wilschut, Jan ^a   De Haan, Aalzen ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Mymetics BV   (Netherlands)

Author keywords

Adjuvant; Cotton rat; Enhanced respiratory disease; Monophosphoryl lipid A; Respiratory syncytial virus; Vaccine; Virosomes

Indexed keywords

BETA ACTIN; FORMALDEHYDE INACTIVATED VACCINE; GAMMA INTERFERON; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; PHOSPHORYL LIPID A; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COTTON RAT; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOLOGY; LUNG ALVEOLITIS; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS TITRATION;

ADJUVANT; COTTON RAT; ENHANCED RESPIRATORY DISEASE; MONOPHOSPHORYL LIPID A; RESPIRATORY SYNCYTIAL VIRUS; VACCINE; VIROSOMES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; LIPID A; LUNG; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SIGMODONTINAE; VACCINES, VIROSOME;

EID: 84887167187     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12112     Document Type: Article

References (36)

1. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435-448.
2. Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-434.
3. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-421.
4. Murphy BR, Prince GA, Walsh EE et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986; 24:197-202.
5. Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988; 26:1595-1597.
6. Delgado MF, Coviello S, Monsalvo AC et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15:34-41.
7. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151:2032-2040.
8. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996; 70:2852-2860.
9. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65:3231-3240.
10. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011; 239:178-196.
11. Garçon N, Wettendorff M, van Mechelen M. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 2011; 11:667-677.
12. Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs 2008; 17:1051-1065.
13. Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JCG. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 2006; 24:5027-5035.
14. Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS ONE 2012; 7:e36812.
15. Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001; 82:2881-2888.
16. Prince GA, Jenson AB, Hemming VG et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 1986; 57:721-728.
17. Niewiesk S, Prince G. Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim 2002; 36:357-372.
18. Blanco JCG, Pletneva L, Boukhvalova M, Richardson JY, Harris KA, Prince GA. The cotton rat: an underutilized animal model for human infectious diseases can now be exploited using specific reagents to cytokines, chemokines, and interferons. J Interferon Cytokine Res 2004; 24:21-28.
19. Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: a safe and immunogenic non-replicating vaccine formulation. Vaccine 2010; 28:5543-5550.
20. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493-497.
21. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011; 239:149-166.
22. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21:425-456.
23. Li-Weber M, Krammer PH. Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat Rev Immunol 2003; 3:534-543.
24. Goswami R, Kaplan MH. A brief history of IL-9. J Immunol 2011; 186:3283-3288.
25. Shen HH, Ochkur SI, McGarry MP et al. A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J Immunol 2003; 170:3296-3305.
26. Steenwinckel V, Louahed J, Orabona C et al. IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol 2007; 178:3244-3251.
27. Maes T, Joos GF, Brusselle GG. Targeting interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol 2012; 47:261-270.
28. Moghaddam A, Olszewska W, Wang B et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006; 12:905-907.
29. Kruijsen D, Schijf MA, Lukens MV et al. Local innate and adaptive immune responses regulate inflammatory cell influx into the lungs after vaccination with formalin inactivated RSV. Vaccine 2011; 29:2730-2741.
30. Neuzil KM, Johnson JE, Tang YW et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 1997; 15:525-532.
31. Kool M, Soullié T, van Nimwegen M et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205:869-882.
32. Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 1994; 12:775-808.
33. Höpken UE, Lu B, Gerard NP, Gerard C. Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J Exp Med 1997; 186:749-756.
34. Humbles AA, Lu B, Nilsson CA et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000; 406:998-1001.
35. Polack FP, Teng MN, Collins PL et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002; 196:859-865.
36. Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470:543-547.